HK Stock Market Move | INNOVENT BIO(01801) rose more than 4%, Ma Shi Du peptide injection with high dose of 9mg received acceptance of market application.

INNOVENT BIO (01801) rose more than 4%, rising 4.42% as of the time of publication, to 98 Hong Kong dollars, with a turnover of 405 million Hong Kong dollars. On the news front, on November 25, INNOVENT BIO announced that the high-dose 9mg of Xerime (mastodatide injection, a dual receptor agonist for glucagon-like peptide-1 "GLP-1" in adults with severe obesity for long-term weight control has been accepted by the China National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) for listing application. Mastodatide is expected to provide a powerful and safe new treatment option for the severe and obese population in China, in addition to weight loss surgery. This listing application is based on the outstanding results of the Phase III registration clinical trial GLORY-2 (NCT06164873) of 9mg of mastodatide in the severe and obese population in China. The study recently achieved its primary endpoint and all key secondary endpoints. It is reported that Xerime (mastodatide injection) 9mg is currently the only GLP-1 drug that can achieve a reduction of more than 20% in weight loss in 1 year with a 2-step dose titration, providing evidence-based medicine for effective weight management for severe and obese patients in China outside of weight loss surgery.